Eric Sheridan: Thanks so much for taking the questions. And maybe a two-parter, if I can, compared to what you have seen historically, is there any way to frame or quantify what you are embedding in the forward guidance for promotional activity or competitive intensity in the next quarter over the holiday period versus what you have seen historically? And is there any sense that you might see a different bent to competition in the industry given some of the inflation dynamics and consumer wallet dynamics out there broadly? Thanks so much for the color.
Sumit Singh: Eric, compared to Q3, the promotional environment is elevated in Q4, this is normal seasonal pattern we see every year heading into the holidays. But within the context of Q4 itself, we believe the promotional environment remains rational and more or less in line with what we have seen in previous holiday periods. And looking forward, we don’t expect the levels of promotions will intensify beyond the current levels that we are seeing. On your second question, we aren’t €“ do we expect competitors to add differently given inflation. The fact that the industry, primarily on the consumables and healthcare side is mapped, I think it allows a discipline in a market. And secondly, supply chains haven’t yet fully recovered.
So, in stock positions are certainly improving, but they are not back to normal to be able to expect hyperactivity. And then third, when you look at hard goods sales that are generally the elastic category, currently, there isn’t much elasticity to be driven given the consumers’ mindset plus the inventory there, it doesn’t €“ like when you look at the contribution from a contribution point of view, it makes up about 15% of our overall sales. So, we are a little more insured there from a spend point of view.
Operator: Thank you for your question sir. Our next line of questions comes from the line of Dylan Carden with William Blair. Your line is now open.
Dylan Carden: Thanks a lot. I guess you guys could decide today to provide any detail on the other revenue line item. I know there is a couple of moving parts there, particularly if you are seeing trade down or any benefit more broadly in the last several quarters in the private label space? And any update on the partnerships with vets or Practice Hub sort of how pharmaceuticals are trending? Thanks.
Mario Marte: Hi Dylan, this is Mario. I will take the first part of that. So, as you know, we don’t desegregate that other line item, other revenue item. But in there, we include not only our pharmacy, but also our private €“ all of our proprietary brand sales specialty, meaning anything that is non-cat type of product, meaning other peptides. As you would expect, that you saw in the hard goods, I will give you context rather than specific numbers. But as you saw in hard goods, though that was an improvement quarter-over-quarter in the terms of decline, a lot of our sales in the private brand space are going to be hard goods. So, just like we sell with third-party or national brands hard goods declined year-over-year. You would have expected something similar on the private brands and other thing. Our healthcare offerings, our pharmacy especially continues to perform really well and to grow faster than the rest of the business. So, I will say that.
